Navigator Medicines, Inc. — SEC Form D Filing
Navigator Medicines, Inc. filed an SEC Form D on September 25, 2026, reporting $10.00M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- September 25, 2026
- Amount reported
- $10.00M
- Round stage
- Series A because a ten million dollar raise in the biotechnology sector typically funds the transition from preclinical target validation to IND-enabling studies.
- Industry
- Biotechnology
- Website
- https://navigatormedicines.com
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Patients suffering from complex autoimmune and oncology diseases lack highly targeted therapies, resulting in poor treatment outcomes and severe systemic side effects from broad-spectrum treatments.
Solution
Navigator Medicines develops a pipeline of novel, targeted biologic therapies designed to precisely modulate disease pathways and improve patient outcomes.
Why now
Recent advancements in translational medicine and high-throughput screening technologies allow researchers to identify and validate novel disease targets with unprecedented speed and accuracy.
Source: SEC EDGAR Form D filing